Prospective Grant of Exclusive Start-up Option License: Use of Oligodeoxynucleotide as Neuroprotectants in Cerebral and Other Ischemic Injury, 51578 [2014-20548]

Download as PDF 51578 Federal Register / Vol. 79, No. 168 / Friday, August 29, 2014 / Notices Dated: August 22, 2014. Jackie Painter, Acting Director, Division of Policy and Information Coordination. [FR Doc. 2014–20598 Filed 8–28–14; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive Startup Option License: Use of Oligodeoxynucleotide as Neuroprotectants in Cerebral and Other Ischemic Injury AGENCY: National Institutes of Health, HHS. ACTION: Notice. This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive start-up option license to practice the inventions embodied in: (E– 147–1999/0 &1) US provisional patent application No. 60/128/898 filed 4/12/ 1999, and PCT application No. PCT/ US00/09839 filed 4/12/2000, and U.S. patent No. 6,977,245 filed 02/06/2002 issued 12/20/2005, and U.S. patent No. 7,960,356 filed 05/17/2005 and issued 06/14/2011, and EP1176966 granted 4/ 3/2013, each entitled ‘‘Oligodeoxynucleotide and Its Use to Induce an Immune Response’’; and (E– 036–2005/0) US provisional patent application No. 60/713,547 filed August 31, 2005, and PCT application No. PCT/ US2006/033774 filed August 28, 2006, and US patent 7,892,569 filed 8/31/2005 issued 2/22/2011, and Canada application number 2620582 filed 2/28/ 08, and Australia patent 2006284889 filed 8/28/2006 issued 12/1/11, and Japan patent 5481068 filed 8/28/2006 issued 2/21/2014, each entitled ‘‘Method of Altering an Immune Response Induced by CpG Oligodeoxynucleotides’’; and (E–214– 2001/0) US provisional patent application No. 60/312,190 filed August 14, 2001, and PCT application No. PCT/ US202/025732, and US patent 7,354,909 filed February 2, 2004 issued April 8, 2008, and US patent 7,959,934 filed March 28, 2008 issued June 14, 2011, each entitled ‘‘Method for Rapid Generation of Mature Dendritic Cells’’ by Klinman et al. (FDA), to Neuralexo, LLC, having a place of business at 17367 Canal Circle, Lake Oswego, Oregon 97035. wreier-aviles on DSK5TPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 15:25 Aug 28, 2014 Jkt 232001 The United States of America is an assignee to the patent rights of these inventions. The prospective exclusive start-up option licensed territory may be worldwide, and the field of use may be limited to: preventative treatment for ischemic injury in organs. DATES: Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before September 15, 2014 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Tedd Fenn, Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Email: fennea@mail.nih.gov; Telephone: 424–297–0336; Facsimile: 301–402– 0220. SUPPLEMENTARY INFORMATION: This invention relates to compositions and methods of use of oligodeoxynucleotides (ODNs) expressing CpG motifs to induce immune responses. These ODN motifs trigger immune system responses which may mediate inflammatory responses to tissue injury, such as those responses following ischemic damage to the central nervous system. Structural differences between various ODNs may stimulate distinct cell populations, allowing selective targeting of immune responses for therapeutic purposes. Non-human primate and animal models using specific ODNs for pharmacological preconditioning have shown that ODNs may act therapeutically as neuroprotectants from ischemic damage. These TLR ligands as may be useful therapeutically as neuroprotectants in ischemic injury. The prospective exclusive start-up option license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive start-up option license may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404 within fifteen (15) days from the date of this published notice. Complete applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive start-up option license. Comments and objections submitted in response to this notice will not be made available for PO 00000 Frm 00053 Fmt 4703 Sfmt 9990 public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: August 25, 2014. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–20548 Filed 8–28–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel ADRC Review Meeting. Date: October 14–15, 2014. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Elaine Lewis, Ph.D., Scientific Review Branch, National Institute on Aging, Gateway Building, Suite 2C212, MSC–9205, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301–402–7707, elainelewis@nia.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS). Dated: August 25, 2014. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–20552 Filed 8–28–14; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\29AUN1.SGM 29AUN1

Agencies

[Federal Register Volume 79, Number 168 (Friday, August 29, 2014)]
[Notices]
[Page 51578]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-20548]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Start-up Option License: Use of 
Oligodeoxynucleotide as Neuroprotectants in Cerebral and Other Ischemic 
Injury

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health (NIH), Department of 
Health and Human Services, is contemplating the grant of an exclusive 
start-up option license to practice the inventions embodied in: (E-147-
1999/0 &1) US provisional patent application No. 60/128/898 filed 4/12/
1999, and PCT application No. PCT/US00/09839 filed 4/12/2000, and U.S. 
patent No. 6,977,245 filed 02/06/2002 issued 12/20/2005, and U.S. 
patent No. 7,960,356 filed 05/17/2005 and issued 06/14/2011, and 
EP1176966 granted 4/3/2013, each entitled ``Oligodeoxynucleotide and 
Its Use to Induce an Immune Response''; and (E-036-2005/0) US 
provisional patent application No. 60/713,547 filed August 31, 2005, 
and PCT application No. PCT/US2006/033774 filed August 28, 2006, and US 
patent 7,892,569 filed 8/31/2005 issued 2/22/2011, and Canada 
application number 2620582 filed 2/28/08, and Australia patent 
2006284889 filed 8/28/2006 issued 12/1/11, and Japan patent 5481068 
filed 8/28/2006 issued 2/21/2014, each entitled ``Method of Altering an 
Immune Response Induced by CpG Oligodeoxynucleotides''; and (E-214-
2001/0) US provisional patent application No. 60/312,190 filed August 
14, 2001, and PCT application No. PCT/US202/025732, and US patent 
7,354,909 filed February 2, 2004 issued April 8, 2008, and US patent 
7,959,934 filed March 28, 2008 issued June 14, 2011, each entitled 
``Method for Rapid Generation of Mature Dendritic Cells'' by Klinman et 
al. (FDA), to Neuralexo, LLC, having a place of business at 17367 Canal 
Circle, Lake Oswego, Oregon 97035.
    The United States of America is an assignee to the patent rights of 
these inventions.
    The prospective exclusive start-up option licensed territory may be 
worldwide, and the field of use may be limited to: preventative 
treatment for ischemic injury in organs.

DATES: Only written comments and/or application for a license that are 
received by the NIH Office of Technology Transfer on or before 
September 15, 2014 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Tedd Fenn, Senior Licensing and Patenting 
Manager, Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Email: 
fennea@mail.nih.gov; Telephone: 424-297-0336; Facsimile: 301-402-0220.

SUPPLEMENTARY INFORMATION: 
    This invention relates to compositions and methods of use of 
oligodeoxynucleotides (ODNs) expressing CpG motifs to induce immune 
responses. These ODN motifs trigger immune system responses which may 
mediate inflammatory responses to tissue injury, such as those 
responses following ischemic damage to the central nervous system. 
Structural differences between various ODNs may stimulate distinct cell 
populations, allowing selective targeting of immune responses for 
therapeutic purposes. Non-human primate and animal models using 
specific ODNs for pharmacological preconditioning have shown that ODNs 
may act therapeutically as neuroprotectants from ischemic damage. These 
TLR ligands as may be useful therapeutically as neuroprotectants in 
ischemic injury.
    The prospective exclusive start-up option license will be royalty 
bearing and will comply with the terms and conditions of 35 U.S.C. 209 
and 37 CFR part 404. The prospective exclusive start-up option license 
may be granted unless the NIH receives written evidence and argument 
that establishes that the grant of the license would not be consistent 
with the requirements of 35 U.S.C. 209 and 37 CFR part 404 within 
fifteen (15) days from the date of this published notice.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive start-up option license. Comments and 
objections submitted in response to this notice will not be made 
available for public inspection, and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.

    Dated: August 25, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-20548 Filed 8-28-14; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.